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INTERGROWTH-21st is a multicentre, multiethnic, populationbased project, being conducted in eight geographical areas (Brazil,
China, India, Italy, Kenya, Oman, UK and USA), with technical
support from four global specialised units, to study growth, health
and nutrition from early pregnancy to infancy. It aims to produce
prescriptive growth standards, which conceptually extend the
World Health Organization (WHO) Multicentre Growth Reference
Study (MGRS) to cover fetal and newborn life. The new
international standards will describe: (1) fetal growth assessed by
clinical and ultrasound measures; (2) postnatal growth of term and
preterm infants up to 2 years of age; and (3) the relationship
between birthweight, length and head circumference, gestational age
and perinatal outcomes. As the project has selected healthy cohorts

with no obvious risk factors for intrauterine growth restriction,
these standards will describe how all fetuses and newborns should
grow, as opposed to traditional charts that describe how some have
grown at a given place and time. These growth patterns will be
related to morbidity and mortality to identify levels of perinatal
risk. Additional aims include phenotypic characterisation of the
preterm and impaired fetal growth syndromes and development of
a prediction model, based on multiple ultrasound measurements, to
estimate gestational age for use in pregnant women without access
to early/frequent antenatal care.
st

Keywords Fetal, growth, INTERGROWTH-21 , newborn, nutri-

tion, preterm, standards.
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Introduction
Antenatal and postnatal care consist mostly of a series of
screening tests of varied complexity, implemented at different levels of care, which together contribute to evaluating
the overall health and nutritional status of each pregnant
woman and newborn baby.1,2 Objective assessments of fetal
and neonatal growth deviations can play a major role in

routine clinical care, as well as maternal and neonatal
health research. The usefulness and limitations of such
screening methods have been evaluated in randomised controlled trials over the last decade.3,4 In some pregnancies
and newborns, especially those that are preterm, there is a
need to monitor growth more closely to decide if clinical
interventions are required. However, international growth
charts analogous to the World Health Organization
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(WHO) Multicentre Growth Reference Study (MGRS)
standards for infants and young children,5,6 developed
using a prescriptive approach, are not available.
This paper summarises the research strategy, methodology and implementation processes across eight geographically defined study sites (Pelotas, Brazil; Beijing, China;
Nagpur, India; Turin, Italy; Nairobi, Kenya; Muscat, Oman;
Oxford, UK and Seattle, USA) and the Project Coordinating Unit, (Nuffield Department of Obstetrics & Gynaecology, University of Oxford, UK), for the studies that
comprise the International Fetal & Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st) Project. It complements the detailed protocol, data collection
forms and operation manuals being used during the project
itself that have been available on our website
(www.intergrowth21.org.uk) from the outset.

Background
In 2006, WHO released its Child Growth Standards for
children aged 0–5 years, which were generated by the
WHO MGRS.5,6 Two characteristics made MGRS unique
and unprecedented in its field: (1) the study included populations from several countries (Brazil, Ghana, India, Norway, Oman and the USA) and (2) a prescriptive approach
was used to select the study populations, i.e. only children
from populations with minimal environmental constraints
on growth were included. This was achieved by recruiting
children of affluent and educated parents, because high
education and family income have been identified as the
environmental variables most likely to be associated with
optimal child growth. In addition, chronic illness, unwillingness to adhere to MGRS feeding recommendations and
maternal smoking were used at study entry as exclusion
criteria.
By virtue of these characteristics, MGRS provided the
strong scientific foundations for developing standards that
indicate how children should grow, as opposed to previous
studies that simply described actual patterns of growth at a
particular time and place. Consequently, the WHO Child
Growth Standards5,6 are now being used worldwide to
judge children’s growth because they demonstrate how
healthy children grow in an environment that allows them
to achieve their full growth potential.
We aimed to extend the concepts promoted by WHO
and the MGRS investigators into fetal and neonatal life.
Our project is, therefore, based on the same prescriptive
approach with international representation. The design,
implementation and conduct of our project, and dissemination of the results, as well as their incorporation into
clinical practice guidelines and healthcare policies, build on
what has been achieved by the international MGRS team,
offering to countries a conceptual continuity between the
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development and implementation of prenatal and postnatal
growth standards.

Conceptual issues guiding the
INTERGROWTH-21st Project
Figure 1 presents the conceptual framework behind the
three primary objectives: the production of three prescriptive, international, multiethnic, growth standards that are
described in the next section. There is considerable evidence to justify using such international standards in the
field of perinatal medicine. For example, most, if not all,
reference values for disease screening or diagnosis are not
ethnicity specific. Epidemiological and clinical studies have
also consistently demonstrated similar growth patterns in
children from high socio-economic backgrounds across
populations,5,6 and growth patterns for both infants and
children are more affected by health, socio-economic status
and environmental conditions than genetic differences.
Furthermore, human growth is a complex genetic trait
involving many genes; it is unlikely to be affected by
genetic variations responsible for characteristics such as
skin colour. Finally, ethnicity-specific standards are impractical tools for use in most multiethnic populations
served by healthcare systems, especially as admixture is
increasing.
The concept of prescriptive growth requires that the
populations used to construct the standards live in environments with no socio-economic constraints on growth,
and receive up-to-date, evidence-based, medical care and
appropriate nutrition. We have followed such principles as
described below. The project design (described under
‘Study characteristics’ in Figure 1) will make the new standards consistent, conceptually, with those recently produced by WHO for infants and young children. We, have
therefore, conducted prospective, population-based, multiethnic studies using standardised methodology in geographical areas where there is high quality maternal and
neonatal care.

INTERGROWTH-21st objectives
The INTERGROWTH-21st Project has five objectives,
involving separate studies. The first three are to produce,
for practical clinical applications and to monitor population trends, three sets of international growth standards
describing:
• Fetal growth from early pregnancy (Fetal Growth Longitudinal Study—FGLS).
• Postnatal growth of preterm infants (Preterm Postnatal
Follow-up Study—PPFS).
• Birthweight, length and head circumference for gestational age (Newborn Cross-sectional Study—NCSS).
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Figure 1. Conceptual framework for the construction of international growth standards based on the prescriptive approach.

These standards will be related to perinatal morbidity
and mortality to identify levels of risk.
The remaining two objectives are:
(1) To investigate the determinants of preterm delivery
and impaired fetal growth in this sample (Preterm
and Impaired Fetal Growth Syndromes Study—PIFGSS).
(2) To develop a prediction model, based on multiple
two-dimensional (2D) ultrasound measurements, for
estimating gestational age during mid–late pregnancy
for use in women without access to early/frequent
antenatal care (Mid-late Pregnancy Gestational Age
Prediction Study—MPGAPS).

Selection of INTERGROWTH-21st Project
sites
The selection of the populations contributing participants
to the project occurred on two levels, cluster and individual. The cluster level involved selecting a geographical area
(e.g. city or part of a city with clear political or geographical limits) followed by the selection, within each area, of
health institutions where women at low–medium risk for
impaired fetal growth attend for antenatal/delivery care and
infant follow-up. At the level of the individual, it involved
selecting, within these populations and hospitals, women or
newborns with specific characteristics required for the project’s different components.

A list of nine potential study sites was created with the
intention of achieving geographical distribution across continents. Previous participation in multicentre observational
studies, including MGRS,7–9 and maternal/perinatal health
randomised controlled trials was considered beneficial. For
logistical reasons, one site was unable to participate leaving
a total of eight, two of which had participated in MGRS
(Figure 2).
Within each geographical area, we identified all institutions that could provide the required participants. Locally
adapted definitions were used for socio-economic characteristics associated with unconstrained growth in these populations, including measures of household income, housing
tenure, education, occupation and employment status using
locally selected cut-off points. These variables have been
recently identified as mediating factors in the relationship
between birthweight and ethnicity.10
To select institutions in developing countries, we first
conducted a census of all hospitals where deliveries take
place in each geographical area and identified those classified locally as ‘private’ or ‘corporation’ hospitals and/or
those serving the middle to upper socio-economic population. However, we have included all institutions in a region
if most deliveries take place in a few central institutions
(e.g. Brazil and China).
The institutions selected in each geographical area delivered >80% of the eligible women in the target population.
We concentrated on institutions with >1000 deliveries per
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Figure 2. Collaborating institutions participating in the INTERGROWTH-21st Project.

year, as it was important to involve as few hospitals as possible for logistical reasons (Figure 3).
The institutions in developing countries serve low-risk
populations as defined by: (1) low birthweight rate <10%
and mean birthweight >3100 g; (2) located at an altitude
<1600 m; (3) perinatal mortality <20 per 1000 live births;
(4) mothers attending antenatal care in these institutions
should plan to deliver there or in a similar hospital
located in the same geographical area; (5) >75% of moth-

ers have attained an educational level greater than the
locally defined cut-off point, and (6) absence of known
non-microbiological contamination such as pollution,
domestic smoke, radiation or any other toxic substances,
evaluated at the cluster level using a data collection form
specifically developed for the project.
We present below the description of the different studies
and the research strategies comprising the INTERGROWTH-21st Project.

Figure 3. Selection of populations for the INTERGROWTH-21st Project.
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1. The Fetal Growth Longitudinal
Study (FGLS)
This study aims to develop: (1) new, international, fetal
growth standards using 2D ultrasound to measure the
most commonly acquired dimensions of fetal size, and
(2) a new, international, symphyseal–fundal height standard.

FGLS individual entry criteria
The methods used to select either a ‘very healthy’ or a
‘healthy’ study population, and the risk factors associated
with intrauterine growth restriction (IUGR) to be excluded
are debatable. The most important considerations for
selecting a ‘healthy’ population with no obvious risk factors
for IUGR or over-growth at the first antenatal care visit
early in pregnancy are: (1) achieving a balance between
strict criteria for risk and external validity of the study
population, and (2) the logistics of screening for factors
that are not part of routine care or for which consensus is
lacking about their effect on fetal growth.
There is an extensive literature on risk factors for preterm delivery and IUGR, particularly in low-income and
middle-income countries, as well as data from our own
large-scale studies that have systematically addressed the
issue.11–19 Hence, in defining the FGLS eligibility criteria,
we could have excluded women with every possible risk
factor for poor pregnancy outcomes. However, we believed
that it was preferable, in the initial screening process, to
select specific factors commonly used to identify women
who would benefit from low-risk, routine antenatal care1
(Box 1).
All women <14+0 weeks of gestation by menstrual dates,
attending their first antenatal care visit in the selected institutions were screened at study entry using the above criteria. This resulted in a study population likely to need only
routine antenatal care, i.e. a group of apparently healthy
women who could follow basic antenatal care models.
Some variables have clear thresholds (e.g. urine or previous
fetal death); for others, the thresholds are less clear-cut
(e.g. maternal height or education)20 and, inevitably, we
had to make some arbitrary decisions.

Estimating gestational age at study entry
Clearly, establishing a very precise determination of gestational age is vitally important for constructing growth standards (in addition to clinical management) and we were
prepared to screen large numbers of women, if necessary,
to obtain the ideal study population.
There are three ways to estimate gestational age early in
pregnancy: (1) the first day of the last menstrual period
(LMP) alone; (2) early (<14 + 0 weeks of gestation) ultra-

Box 1. Women must have the following
characteristics at booking (<14 weeks of
gestation)
a) Aged ‡18 and <35 years.
b) Body mass index ‡18.5 and <30 kg/m2.
c) Height ‡153 cm.
d) Singleton pregnancy.
e) A known last menstrual period with regular cycles (defined as
28 ± 4 days) without hormonal contraceptive use, or breastfeeding in the
2 months before pregnancy.
f) Natural conception.
g) No relevant past medical history, with no need for long-term
medication (including fertility treatment and over-the-counter medicines, but excluding routine iron, folate, calcium, iodine or multivitamin supplements).
h) No evidence of socio-economic constraints likely to impede fetal
growth identified using local definitions of social risk.
i) No use of tobacco or recreational drugs such as cannabis in the
3 months before or after becoming pregnant.
j) No heavy alcohol use (defined as >5 units (50 ml pure alcohol)
per week) since becoming pregnant.
k) No more than one miscarriage in the two previous consecutive
pregnancies.
l) No previous baby delivered preterm (<37+0 weeks of gestation)
or with a birthweight <2500 g or >4500 g.
m) No previous neonatal or fetal death, previous baby with any
congenital malformations, and no evidence in present pregnancy of
congenital disease or fetal anomaly.
n) No previous pregnancy affected by pre-eclampsia/eclampsia,
HELLP syndrome or a related pregnancy-associated condition.
o) No clinically significant atypical red cell alloantibodies.
p) Negative urinalysis.
q) Systolic blood pressure <140 mmHg and diastolic blood pressure
<90 mmHg.
r) No diagnosis or treatment for anaemia during this pregnancy
(haemoglobin levels will be monitored throughout pregnancy).
s) No clinical evidence of any other sexually transmitted diseases,
including syphilis and clinical trichomoniasis.
t) Not in an occupation with risk of exposure to chemicals or toxic
substances, or very physically demanding activity to be evaluated by
local standards. Also women should not be conducting vigorous or
contact sports, such as scuba diving or similar activities.

sound alone assuming that the early growth of the fetus
has been normal, or (3) LMP and ultrasound combined.
The implications of these different methods on research
findings have recently been discussed.21 Dating by LMP
and ultrasound is clearly an assessment of different parameters and both methods have their limitations. Although it
has been suggested that ultrasound before 14+0 weeks of
gestation may be better by an average of 2–3 days in predicting the date of delivery, in clinical practice, both methods are often used in combination and it is now generally
recommended that both should be retained for fetal growth
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monitoring. Based on the 2004 Birth Cohort from the Brazilian Study Centre, we anticipated that 10% of women
in these selected subpopulations would have an unreliable
LMP, although this figure may be as high as 30% in the
general population.
Taking all factors into consideration, we decided not to
base gestational age solely on LMP or early ultrasound;
rather, we chose a combined, two-stage process to determine
gestational age. In women with a reliable LMP and regular
periods who were 9+0 to 13+6 weeks pregnant, their gestational age was confirmed with a standardised, ultrasound
crown–rump length (CRL) measurement, using an internationally recognised chart.22 If the difference between the CRL
and LMP estimates was £7 days, the LMP was considered
valid and taken as the true biological date. Those women
with differences >7 days were not considered for the study
because either the LMP estimation may not be reliable or the
discrepancy indicated an early fetal growth alteration.
Hence, we did not include participants if fetal size on
ultrasound at the first scan was discrepant from the LMP.
If ultrasound alone was used to estimate gestational age
and the measurement was erroneous, that error would be
incorporated into the growth chart. This is a circular argument that we tried to avoid. Furthermore, the early ultrasound estimation of gestational age has the limitation that
all fetuses with a given CRL value will have the same gestational age, which is clearly not possible, i.e. using an ultrasound-based gestational age, such as CRL alone, excludes
any biological variability, which is a major limitation of
previous data evaluating fetal growth.23,24

Nutritional adequacy during pregnancy
The study population was expected to have an adequate
nutritional status, based on the same conceptual approach
used in MGRS. In that study, it was assumed from the outset that children recruited from affluent populations consumed adequate complementary foods. This proved to be
the case when their complementary diets were analysed.25
In the present study, we adopted the same concept for
women but, in addition to selecting those with adequate
nutritional status before pregnancy, we developed general
nutritional guidelines for pregnant/lactating women, suitable for local use, based on the best available evidence, for
promotion among the participating mothers and care providers.
Routine nutritional supplements, e.g. protein or energy,
were not given because: (1) they are not components of
the recommended antenatal care package in these populations,1 and (2) we recruited women with adequate nutritional status. Iron-folate supplementation was prescribed
if necessary for anaemia during/after pregnancy, but routinely given only if such a policy was in place in the institution. A similar position was taken with calcium
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supplementation for the prevention of pre-eclampsia and
preterm delivery.
Women were asked if they were taking nutritional supplements; this information was recorded at each antenatal
care visit. It is not practical in a study of this size to measure adherence in any other way or to obtain individual
intakes, e.g. 24-hour recall, considering the poor reliability
of such instruments for individual assessment. Finally, as
an objective outcome of the nutritional status during pregnancy, we monitored weight gain at each visit using standardised methodology.

Pregnancy follow-up
Women in FGLS received standardised antenatal care based
on the recommended WHO new antenatal care package
(modified or upgraded according to local practices).1 All
participants were followed throughout pregnancy from
their first clinic visit, irrespective of the pregnancy outcome. As a general principle, the number of exclusions
from the analysis for the creation of the final fetal growth
standards will be as small as possible. They will be confined
to fetuses with congenital abnormalities (based on a final
evaluation at birth); multiple pregnancies that were not
identified at recruitment; mothers diagnosed with catastrophic fetal death or very severe medical conditions not
evident at recruitment (e.g. cancer, HIV); those with severe
pregnancy-related conditions requiring hospital admission
(e.g. eclampsia or severe pre-eclampsia), and those found
later in pregnancy to fulfil one of the exclusion criteria
(e.g. women who started to smoke during pregnancy).
Hospital admission per se is not a reason for exclusion:
women admitted simply for ‘observation’ still contribute
data to the fetal growth standards unless they developed
one of the conditions listed above. All sites are malaria-free
eco-zones. Nevertheless, we adhered to local protocols and
excluded from incorporation in the fetal growth standards
any woman with evidence of malaria infection during the
pregnancy. The final definitions of these conditions were
approved by the Project Steering Committee before analysing any data.
To date, FGLS has had fewer follow-up problems than
many of our previous randomised controlled trials. This
was expected because we are studying well-educated
women who are enthusiastic about the aims of the study.
Nevertheless, to ensure that the loss to follow-up remains
as low as possible, we maintain very close contact with participants, reminding them about imminent visits and conducting home visits if necessary.

FGLS 2D ultrasound measurements
Detailed descriptions of the ultrasound protocol and the
extensive quality control measures being employed in FGLS
are presented elsewhere.26,27 In preparing the protocol, it
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became clear that performing more than six ultrasound
examinations after the dating scan would present undesirable logistical problems and possibly cause inconvenience
to mothers. It was also evident that a minimum growth
change has to occur between visits to be reliably measured
by ultrasound, considering the errors resulting from the
equipment and observers. Hence, even if growth velocity
by unit of time (e.g. 1 week) for some measurements is
high during certain gestational periods, the actual change
may not be reliably measured.
We considered alternative spacing between measurements, such as longer intervals early (e.g. 8 weeks), and
shorter ones (e.g. 4 weeks) later, in pregnancy. However,
there is evidence that measures such as biparietal diameter
and femur length continue to increase almost linearly until
34 weeks. The need to coordinate multiple antenatal visits,
at different time intervals for a large number of women,
was an argument against adopting variable timings. Finally,
as women were recruited more or less spread across the
9+0 to 13+6 weeks of gestation range, we expected a distribution of visits throughout pregnancy in most centres.
Therefore, after the first scan (9+0 to 13+6 weeks), we performed scans targeted at 5-weekly (±1 week) intervals, i.e.
14–18, 19–23, 24–28, 29–33, 34–38 and 39–42 weeks. So, a
woman could have scans at 10, 15, 20, 25, 30, 35 and
40 weeks or 11, 16, 21, 26, 31, 36 and 41 weeks depending
upon the gestational age at recruitment and duration of
pregnancy. This has the advantage of providing greater
coverage of the whole pregnancy and easier scheduling of
scans, especially as we allowed a leeway of up to a week
either side of each planned scan visit. A standard ultrasound examination includes five measurements, in addition
to biparietal diameter and femur length, at each visit from
14 weeks onwards: occipito-frontal diameter; head circumference; transverse abdominal diameter; anterior–posterior
abdominal diameter, and abdominal circumference.
All clinical data in FGLS are obtained as part of routine
practice and available to care providers at all times. Our
policy with regard to the ultrasound findings has been as
follows: (1) the gestational age estimate is incorporated
into the medical records; (2) an ultrasound examination
for structural, congenital malformations is performed at
the time of the third scan before 24+0 weeks of gestation, if
this conforms with local practice, and the results are incorporated into the medical records, and (3) as far as 2D
ultrasound measurements are concerned, after the blinded
values have been submitted electronically to the dataset, the
mean measurement is made available for clinical use.
Finally, as there are concerns about the misuse of ultrasound for sex selection, especially if the practice is illegal,
we were extremely vigilant in regions where this practice is
known to occur and we continuously monitored sex ratios
in the sample.

FGLS symphyseal–fundal height measures
We also aim to produce a new, international, symphyseal–
fundal height standard from FGLS to update the one we
first produced 30 years ago based on a single site sample.28
The present study is the first of its type ever conducted
and the tool will aid antenatal care at the primary-care
level. Symphyseal–fundal height measurements are being
taken at the same time as the ultrasound scans, using similarly rigorous protocol-driven methods, i.e. blinded, duplicate measurements, followed by the same clinician (see
www.intergrowth21.org.uk). They will be used to produce a
standardised, validated, multiethnic chart, in a selected
healthy population, to replace those used in primary
healthcare units and hospitals around the world.
To summarise, Figure 4 presents the patient flow in
FGLS, highlighting the study forms being used. This flow
chart is continually populated by the actual numbers
enrolled using our centrally coordinated, online, data management system.

2. The Preterm Postnatal Follow-up
Study (PPFS)
The aim of this study is to develop postnatal growth charts
for preterm newborns based on the conceptual principles
presented recently by our group.29,30

PPFS individual entry criteria and follow-up
All preterm newborns (‡26+0 but <37+0 weeks of gestation) from the FGLS cohort are being followed for
8 months after delivery to evaluate postnatal growth.
Studying all preterm infants born to mothers selected
using the prescriptive approach (i.e. pregnancies at low
risk of fetal growth alterations) allows evaluation of the
rate of preterm delivery to be expected from such a lowrisk population.
Our strategy makes it possible to study mostly preterm
newborns born after 32+0 weeks of gestation until they
reach ‘term’, with at least 5 months of ‘true’ (after term)
postnatal life. Although we are following all preterm newborns, we are not including those born £30+0 weeks of
gestation in the growth standards because of the associated
severe morbidity and mortality, and consequent need therefore for intensive care. Indeed, we are observing that in this
selected pregnant population even the rate of preterm birth
<34+0 weeks of gestation is <1%. We are, however, following these subgroups of very preterm infants for exploratory
analysis of their growth pattern across these populations.
In addition, using the same protocol, maternal entry criteria and standardisation procedures, we have studied (for
separate analysis) all preterm births in the study institutions within the 30+0 to 34+0-weeks of gestation range, even
if the mothers were not part of FGLS.
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Figure 4. The patient flow during the Fetal Growth Longitudinal Study.

A fixed follow-up period (rather than a ‘postnatal age
limit’) was chosen to simplify running the study and
reduce loss to follow-up (Figure 5). Nevertheless, an

16

analysis based on the time from conception (corrected
age) will be performed to compare preterm babies with
their in utero counterparts conceived around the same
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Figure 5. The patient flow during the preterm postnatal follow-up study.

time. This relatively short follow-up period should reduce:
(1) inconvenience to the mothers, (2) the need for home
visits, and (3) the study’s cost and complexity. Finally,
although we wish to produce new growth charts for the
first 6 months of life, we have extended the follow-up
period to 8 months for these infants to avoid the socalled ‘right-edge’ effect in the construction of the growth
standards.31
From the total preterm population in FGLS, we shall
select newborns to be included in the PPFS standards
who have met the criteria of ‘healthy or stable’ preterm
decided a priori. We recognise that this is a difficult definition and have discussed its concept and implications in
detail in a recent publication.30 In short, preterm infants
contributing to the new standards should be free of congenital malformations and major neonatal conditions
associated with impaired postnatal growth. They should
have received standardised, evidence-based care and been
breastfed exclusively/predominantly for as long as possible
based on current recommendations. A detailed description
of these criteria and the definitions to be used are presented in Box 2 and Table 1. This strategy should provide
a population that is conceptually as close as possible
(adapted to the level of maturation of these preterm
infants) to the prescriptive approach used to construct the
MGRS standards.
The INTERGROWTH-21st Neonatal Group, in collaboration with international advisors, have standardised clinical management across sites and described the clinical

Box 2: Characteristics of prescriptive standards for
monitoring preterm postnatal growth
Characteristics
Multiethnic, population-based, prospective data collected under
recent medical care.
Healthy, well-nourished maternal population.
Early evaluation of gestational age confirmed by ultrasound examination before 14 weeks.
Inclusion only of preterm deliveries (not using low birthweight as a
proxy).
Prospective ultrasound measures of fetal growth to exclude fetuses
with evidence of impaired fetal growth.
Preterm infants included only if they do not have major neonatal
complications, neonatal surgery, congenital malformations or death in
the complete follow-up period.
Standardisation of feeding practices and newborn care among study
centres.
Standardisation of anthropometric measurements including use of
the same equipment and techniques.
High frequency of anthropometric measurements during periods of
fast growth (e.g. every 2 weeks during the first 2 months).
Follow-up period during infancy to allow interface with WHO child
growth standards.
Adequate sample size for each range of gestational ages to allow presentation by Z scores and centiles.

conditions that are exclusion criteria for the growth standards to facilitate uniform diagnosis across sites. This
information and our operations manual (see www.intergrowth21.org.uk), with standardised data collection forms,
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Table 1. Criteria for evaluating preterm newborns according to complications associated with postnatal growth
Organ or
system

Physiological
immaturity, leading
to increased risk of

Conditions associated
with a lack of organ
maturation

Brain

IVH, Papile’s grades I–IV
PVL, de Vries’ grades I–IV
Neurological impairments

IVH, grades I–II
PVL, grades I–II

Lung

Respiratory distress

Respiratory distress syndrome,
not leading to
bronchopulmonary dysplasia
Apnoea of prematurity
Transient tachypnoea of
the newborn
Not requiring surgery
NEC, stage I
Parenteral feeding for £7 days
Gastro-oesophageal reflux

Apnoeas

Heart
Gastrointestinal

Patent ductus arteriosus
NEC, Bell’s stages I–III
Parenteral feeding
Gastro-oesophageal reflux

Liver

Hyperbilirubinaemia

Kidneys

Renal failure

Eyes

Retinopathy

Immune system
Other

Infections
Temperature instability

Requiring or not requiring
blood exchange transfusion
Transitory renal failure not
requiring dialysis
Low urinary output and/or
creatinine >1.0 for <3 months
Retinopathy stages I and II
No sepsis
Low temperature
Continuous stoppage of
enteral feeding for £3 days

Pathological conditions

IVH, grades III–IV
PVL, grades III–IV
Cerebral palsy
Neurological impairments
Hydrocephalus requiring
ventriculoperitoneal shunt
Respiratory distress syndrome,
leading to bronchopulmonary
dysplasia or chronic lung disease

Requiring surgery
NEC, stage II–III
Exclusive parenteral feeding >7 days
Complicated gastro-oesophageal
reflux/short bowel syndrome
Focal intestinal perforation
Kernicterus
Any renal failure requiring dialysis
Low urinary output and increased
creatinine levels for >3 months
Retinopathy stages, III, IV, V
Complete blindness
Sepsis
Stoppage of enteral feeding >3 days

IVH, intraventricular haemorrhage; NEC, necrotising enterocolitis; PVL, periventricular leukomalacia.

have harmonised the implementation of the study across
the participating neonatal units. Adherence to these protocols is being monitored by the Project Coordinating Unit
and the Neonatal Group (in collaboration with the international advisors).
Clearly, for some subgroups of very preterm infants, as
discussed above, this study will allow only exploratory analyses; however, it is still worthwhile because of the unique
opportunity to study fetal and postnatal preterm growth
longitudinally. Some babies, especially those born before
34+0 weeks of gestation, are being managed in a neonatal
intensive care unit (NICU) for several days. Measurements
of these babies are being taken as described in the study
protocol, but in accordance with the clinical status of the
infant and the unit’s protocols. To ensure that ‘clinically
stable’ babies are comparable across different NICUs, the
Neonatal Team is conducting regular standardisation
and monitoring activities based on the study manual.32
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Ultimately, in such an acute clinical care setting, final judgements are made by the attending staff; realistically, this is
how the growth standards will be used in practice anyway.
The postnatal anthropometric measurements are weight,
length and head circumference. Abdominal circumference
is not included because it is not used in routine neonatal
practice and respiratory movements in these tiny newborns
make its measurement unreliable. The three measurements
(plus a standard clinical evaluation and records of morbidity and food intake) are being taken every 2 weeks during
the first 8 weeks, and then every 4 weeks until 8 postnatal
months, using essentially the same methodology employed
in MGRS.6 The only logistical difference is that, in the
present study, measures, interviews and clinical evaluations
are conducted at a special follow-up clinic in the corresponding hospital, provided that the clinical condition of
the infant and routine local care permit this. Routine home
visits (as conducted in MGRS) are not taking place, except
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for those mothers who do not comply with the protocol’s
scheduled visits or those newborns that, because of local
customs, may only be evaluated at home during the first
month of life. The preterm babies have a maximum of 11
follow-up visits over 8 months.

3. The Newborn Cross-Sectional Study
(NCSS)
The aims of NCSS are to: (1) produce birthweight, length
and head circumference for gestational age standards
describing fetal size at birth, and (2) provide data for epidemiological studies of the different phenotypes of the
impaired fetal growth and preterm delivery syndromes. The
relationship of size at birth with neonatal morbidity and
mortality is also being examined. The complete NCSS population includes two subpopulations: one selected using the
FGLS entry criteria (the same questions were included in the
data collection forms for both studies) to construct the prescriptive standards of size at birth. The second, composed of
the remaining newborns from higher-risk pregnancies, will
contribute to the epidemiological analyses and the evaluation
of the new standards as related to neonatal morbidity and
mortality. Hence, NCSS is a descriptive, population-based
study that aims to include all babies born within the INTERGROWTH-21st geographical areas during a fixed period of
12 months (the actual period varies across sites to enable
the target of 7000 deliveries per site to be attained). Consequently, NCSS includes an ‘FGLS-like’ population, as well as
the infants born to mothers enrolled in FGLS itself. Having
data on both groups will allow us to understand the similarities in terms of maternal and fetal characteristics, which will
provide external validity for the fetal growth standards.
The overwhelming majority of babies in NCSS will have
had their gestational age confirmed by ultrasound at their
first antenatal visit and close to 80% of the mothers will
have received care early (<24+0 weeks of gestation) in pregnancy. This has been achieved because all the hospitals in
the INTERGROWTH-21st Project adopted a policy, during
the preparatory phase of the study, of confirming gestational age with a dating ultrasound examination at the first
visit. The strategy of including the complete newborn population allows us not only to study a large number of preterm and growth-restricted infants, as well as their
subgroups, under a wide range of conditions affecting these
outcomes, but also to understand the epidemiological distribution of these groups and their associated risk factors
in populations. We are also able to compare the total
underlying populations across sites in terms of sociodemographics and pregnancy outcomes.
All newborns during the study period, including those
admitted to NICU, special care or referred to another level
of care, are assessed on a daily basis until hospital discharge

to document severe morbidities and detect neonatal deaths.
We have also made strenuous efforts to coordinate and
promote evidence-based care and promoted breastfeeding
practices for all neonates using specific protocols agreed
among the institutions’ lead neonatologists.2 We recognise
that differences in practice will persist despite our best
efforts. However, we believe this is unavoidable in a pragmatic study such as this, which is trying to reflect what
happens in routine clinical practice. Furthermore, we are
similarly making strenuous efforts to standardise the main
protocols for feeding practices in each NICU.32 Implementation of these protocols is monitored during the routine
site visits by members of the Project Coordinating Unit,
and the Neonatal and Anthropometric Teams.
Birth size for gestational age standards, developed using
the subpopulation of NCSS selected using FGLS criteria
(i.e. the ‘FGLS-like’ population), will be related to indicators of perinatal outcome to establish risk levels associated
with different growth patterns. The ‘ideal’ outcome is perinatal mortality, but its anticipated infrequent occurrence
(<1.5%) in this low–medium risk population makes it
unrealistic to have a sample large enough for the necessary
number of events across the gestational age distribution.
We have therefore decided to use an unweighted composite outcome, including at least one of the following conditions: stillbirth, neonatal death occurring up to hospital
discharge of the newborn, and newborn stay in NICU for
‡7 days. This index requires no standardisation of clinical
diagnoses across hospitals and is accepted as a marker in
large, international, population-based studies of newborns
that died or were severely ill. Other groups have successfully
used these composite indices.33–35 It could be argued that intrapartum stillbirth may not be completely related to fetal
growth and should not be included in this index. We believe
this is a valid point but as it will not be possible to separate
those intrapartum deaths that are related to IUGR from
those that are unrelated, we are keeping it in the index.
The index is a good proxy for adverse perinatal outcomes,
including severe morbidity, and obviates the need for uniform neonatal diagnoses across NICUs. It has the disadvantage that it only includes events up until hospital discharge.
Hence, it risks excluding from the total number of early neonatal deaths some cases of healthy, mostly term babies delivered vaginally who die after early hospital discharge, or those
who develop severe complications £7 days postpartum and
do not return to the same hospital for care. However, missing these isolated cases was considered logistically preferable
to establishing a follow-up regimen requiring universal home
visits up to 28 days postpartum. Nevertheless, in some sites
with registration systems, it will be possible to explore how
many later neonatal deaths were missed.
In summary, for NCSS, we are including all newborns
delivered at the institutions that cover >80% of all deliver-
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ies in the geographical areas selected for the project. These
deliveries occur over a 12 month study period or up to the
point when the target sample of 7000 newborns is reached.
The FGLS population includes women from these underlining populations who have agreed to participate and meet
the individual selection criteria until the target sample
number is reached. For PPFS, we are enrolling all preterm
babies from the FGLS cohort.

4. The Preterm and Impaired Fetal
Growth Syndromes Study (PIFGSS)
The complex interactions between risk factors, clinical presentations and underlying biological processes for these syndromes in relation to adverse perinatal outcomes are poorly
understood. Moreover, the failure to understand the heterogeneity of preterm birth and IUGR is now accepted as a
major limitation in understanding and so preventing these
syndromes.36–38 The objective of this study is, therefore, to
explore and validate phenotypic subgroups of the preterm
and IUGR syndromes in the population-based NCSS worldwide. Hence, we will be able to estimate both relative and
attributable risks for aetiological and risk factors.
To identify risk factors, data collected during routine
and specialist antenatal care from all women delivering in
the institutions over a fixed period are being included. A
summary antenatal and delivery form was introduced into
these institutions, which conforms with: (1) the new WHO
model of antenatal care for basic routine care,1 and (2)
local protocols for special cases, standardised by us from
previous trials in pre-eclampsia, hypertension, urinary tract
conditions, and intrapartum and postpartum care. An
important conceptual issue is that we do not aim to detect
any new, unexplored risk factors. Rather, we plan to determine how known risk factors and clinical conditions, which
are routinely recorded during standard antenatal care, are
distributed or cluster in the main, preterm and IUGR, phenotypic subgroups across these populations.
Specifically, we plan to investigate the determinants of
preterm delivery and small for gestational age newborns
from clinical and pregnancy-related, as well as routine laboratory, demographic and socio-economic, variables
obtained from all women attending the study sites without
exclusion (as opposed to FGLS, which aims to produce
fetal growth standards from a sample of selected, healthy
women). It would, of course, be very interesting to collect
more detailed information about other variables such as
placental pathology and cervical length, or test biomarkers,
e.g. of inflammation or infection. However, the question,
as always, is when to stop adding more variables to an
already complex population-based study, particularly as
some of these screening tests are not clinically relevant at
present. Finally, as we have the complete birth population,
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we shall explore the gestational age cut-off points for the
definition of preterm delivery to validate the standard
(clearly arbitrary) <37+0 weeks of gestation cut-off point.
We will apply several statistical strategies to understand the
different components of the 3500 preterm newborns
(<37+0 weeks of gestation) or close to 5000 IUGR newborns
(<10th centile) in the total NCSS population. Initially, we will
consider the classic preterm subgroups based on the mode of
delivery, e.g. induced versus spontaneous deliveries; premature rupture of membranes; pre-eclampsia-related versus
smoking-related or unexplained IUGR, as well other pathological and physiological conditions.13 However, the most
innovative part of this analysis will be the investigation of new
phenotypic classifications based on associations among aetiological factors, clinical events, initiation of parturition and
pathway to delivery. Cluster analysis and similar data reduction strategies to evaluate how sets of variables are grouped to
determine subgroups of preterm birth will be explored. Once
phenotypic subgroups are defined, their associations with risk
factors and perinatal outcomes will also be examined. Lastly,
we intend to explore several factors that might explain variability in fetal growth across populations.39,40

5. The Mid–late Pregnancy Gestational
Age Prediction Study (MPGAPS)
We aim to develop a prediction model, using multiple,
prospectively collected, 2D ultrasound measurements, to
estimate gestational age at a single visit during mid–late
pregnancy (>24+0 weeks of gestation). Current ultrasoundbased gestational age estimation in infrequent attendees or
women with limited access to care is usually determined by
a single measurement, e.g. biparietal diameter, but the estimates have large errors, wide confidence intervals, and
assume that fetal growth has been similar to that of the
population from which the equations were derived. We are
planning to develop equations using several ultrasound
measures taken at a single visit which, if achievable, would
be a major contribution to the care of high-risk women
attending hospitals only once or twice late in pregnancy.
We are also planning to produce new international equations to estimate gestational age before 14+0 weeks of gestation from CRL measures to replace the large number of
equations that are presently used.

General sample size considerations
FGLS
Sample size calculations for growth standards have not
been extensively developed and therefore are supported by
a limited literature. We reviewed several strategies and estimated that the target sample of 500 pregnant women per
population group should be adequate, after excluding
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Figure 6. A population flow diagram for the INTERGROWTH-21st Project.

women with complicated pregnancies and those lost to
follow-up. This sample size is larger than most previous
longitudinal studies, even if each study population is considered separately, and adequate to explore site-specific differences. We estimated that fewer than 5% of women
would be lost to follow-up (based on an average figure of
3% in our previous large trials). We also adjusted for the
fact that 3% of women will be excluded from the study
population to be used in the preparation of the fetal
growth standards because of developing problems severe
enough to affect fetal growth.

PPFS
A cohort of 250 preterm babies will be recruited from
FGLS for PPFS. It is expected that the gestational age distribution will provide a total of 200 babies >34+0 weeks of
gestation (those between 26+0 and 30+0 weeks of gestation
will be followed, but will not be part of the standards). Only
the subgroup of babies free of major clinical complications,
as previously described, will be used to create the standards.
We recognise that the sample size calculations of FGLS are
influenced by logistical issues and the need to provide preterm newborns to be part of PPFS rather than statistical calculations alone. However, it is still a large sample by
preterm study standards and we shall have very detailed follow-up data, increasing the power of the sample for creating
charts. We consider that having a full set of fetal and newborn growth patterns from a cohort of preterm newborns is
important, even without the power to explore gestational
age subgroups or early postnatal morbidity.
NCSS
We are aiming for a total of 56 000 newborns with very
detailed information, which will provide a sample of 40%
eligible babies for the newborn standards, using the same

criteria as for the FGLS population (the ‘FGLS-like subpopulation’). We expect to include overall 2000 newborns
with a positive, severe perinatal morbidity and mortality
index, our established primary outcome.

Summary of the study populations
and their flow
Figure 6 shows the population-based nature of the project
and the relationships between subpopulations. We believe
this comprehensive, yet integrated, series of study
populations makes the INTERGROWTH-21st Project
unique. The populations of mostly low- to medium-risk
women were selected using institutional level criteria; these
56 000 women are included in NCSS. From this population, using criteria at the level of the individual, we have
identified women at low risk of IUGR (‘FGLS-like population’), from which women in FGLS itself are recruited. This
cohort is being followed from <14+0 weeks of gestation to
delivery to produce the fetal growth standards. Those
babies born prematurely (‡26+0 but <37+0 weeks of gestation) to women in FGLS are being followed for 8 months
after birth in PPFS. Lastly, data from NCSS and FGLS are
contributing to two other separate studies, PIFGSS and
MPGAPS, respectively.

Data collection instruments
All documentation and forms used in the INTERGROWTH-21st studies were prepared by the Project Coordinating Unit, tested at the local level and introduced into
the specially developed electronic data management system.
All forms are integrated and linked to reduce duplication
in the data collection process and facilitate data quality
control mechanisms. We are only collecting data that are
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Figure 7. The structure and management of the INTERGROWTH-21st
Project.

relevant to the specific aims of the studies, i.e. we have
tried hard to eliminate unnecessary or duplicate data collection, as collecting too much inevitably reduces data
quality in large field studies. One example is our decision
not to collect detailed individual nutritional intake from
this well-nourished, healthy population. A more detailed
description of the data collection system, including the
actual forms, and the quality control strategies is presented
in another paper of this supplement.41

Assessing similarities among the
populations of fetuses and newborns
whose mothers’ health, nutritional
and care needs are met
To assess any differences in the populations of fetuses and
newborns (whose mothers have optimal health, nutritional
status and obstetric care), we will follow the basic principles adopted in MGRS.5 As in that study, we consider that
the main question to ask is whether or not the variability
across populations for any given growth parameter is larger
than the variability of the same parameter within populations. However, this is not the same as saying that the populations do or do not have identical growth.
To compare growth across populations, the recommended measures in the nutritional field are fat-free mass
indicators, e.g. infant length, as they are: (1) resistant to
skewing in response to ‘excessive nutrition’; (2) normally
distributed (unlike fat-related indicators); (3) more precise
than fat-related indicators; and (4) they were used to construct the MGRS standards, which provides a conceptual
link between the projects.
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We consider a number of fat-free indicators in the fetus to
be the counterparts to length or height in infants and children. These are: (1) CRL, which is generally accepted as the
best ultrasound marker for fetal size at <14+0 weeks of gestation, and (2) head circumference in later pregnancy, as it is
widely used in clinical practice and more resistant to fetal
environmental insults (the so-called ‘brain-sparing effect’)
than abdominal circumference. Importantly, head circumference is also the only measure available from early gestation
(>14+0 weeks of gestation) to childhood. Femur length, the
other potential linear measure, is routinely recorded in pregnancy but it represents only a small part of newborn total
length and does not have a newborn counterpart.
Therefore, we decided that the main fetal indicators to
be used to make judgements on the similarity of fetal
growth patterns across these low-risk populations will be
CRL and head circumference, complemented as a secondary parameter by femur length. For all newborns and preterm infants we will use, as in MGRS, length at birth and
in the first 8 months as the main indicator for such comparisons. The conceptual basis for the population comparisons in the INTERGROWTH-21st Project is, therefore,
entirely consistent with MGRS.

Structure and management of the
project
This comprehensive project was planned as a large-scale,
worldwide, collaborative effort (Figure 2). It primarily
involves eight participating institutions in widely spread geographical areas and their corresponding research units that,
in coordination with the local health authorities, interact
with the Project Coordinating Unit at the University of
Oxford (Figure 7). This structure facilitates integration of
the large number of researchers and clinicians needed to
implement this multifaceted project, as well as expert advisers and groups. They are vital to the success of a project of
this complexity, because not all the expertise required was
available in the primary research institutions and external
scrutiny of the study procedures is also necessary to reduce
bias. Furthermore, we recognised that changing medical
practice, especially in disciplines such as obstetric ultrasound, requires strong political support and credibility.
Therefore, we enrolled specific research support units in
data management and analysis; ultrasound quality control;
neonatal care; anthropometric quality control and standardisation, and perinatal epidemiology (Figure 7). The
standardisation process for ultrasound measures is, to the
best of our knowledge, unique and complemented by
anthropometric standardisation similar to that used in
MGRS. Each of these separate units is independent of the
daily running of the project to provide, as far as possible,
unbiased assessments. Each is led by a recognised world
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expert in the field and has four or five members. In total,
we estimate that this large-scale, international collaboration
involves over 200 scientists, clinicians, researchers and collaborators supporting close to 60 000 families with the aim
of improving maternal and infant health worldwide.
We believe that this model promotes high-quality
research and helps the studies to be completed in a relatively short period of time. Importantly, we have created a
dynamic, independent, international network of channels
reaching the local level, for implementation of effective
interventions. In our opinion, it should replace the classic
unilateral model of collaboration.

Discussion
In this paper, we have described the structure and organisation of a comprehensive research project designed to elucidate the normal pattern of fetal, neonatal and preterm
growth across different geographical areas from conception
to infancy, as recommended 20 years ago by WHO’s corresponding Expert Committee.42
We also aim to explore the characteristics of subgroups
of premature newborns and/or those with impaired fetal
growth to gain a better understanding of these conditions.
This project, we believe, is unique because it combines the
following characteristics: (1) it uses a prescriptive approach
to construct growth standards for fetuses and newborns
along the lines recommended by WHO advisory committees and following MGRS;6 (2) unlike most of its obstetric
predecessors, it is population-based rather than hospitalbased; (3) it covers different ethnic populations across continents; (4) it has a comprehensive, standardised, quality
control strategy for all fetal ultrasound measures (seldom
used in previous studies) and newborn anthropometric
measures, run by a centralised quality control unit; (5) it
has a large sample size that allows stratification and exploration of a wide range of biological questions; (6) it relates,
for the first time, longitudinal fetal growth patterns to perinatal outcomes to establish levels of risk associated with
different growth trajectories; (7) the epidemiological evaluation of the preterm delivery and IUGR syndromes is
based, for the first time, on new phenotypic classifications
that depart from the classical, descriptive subgroups based
only on delivery information, e.g. premature rupture of
membranes or caesarean section; (8) for these epidemiological analyses, gestational age is estimated accurately using
both LMP and early ultrasound examination, standardised
across all countries; and (9) it will provide specific clinical
products (e.g. a symphyseal–fundal height standard) for
use at different levels of care as primary screening tools.
Of course, implementing a project of this nature, which
includes studies being performed across several continents,
presents major challenges for any research team. Recruiting

56 000 pregnant women from eight centres is a huge
task, specifically as the number of eligible participants for
some studies has varied across sites and maternity units.
We anticipated an average eligibility rate of 60% for lowrisk women. However, the actual rate was lower (40%) in
some populations, especially in developed counties, paradoxically because of, for example, higher than expected
smoking rates and the very high proportion of overweight
and older women. Fortunately, each centre devised local
strategies to maximise recruitment rates for FGLS, which
are described in the country-specific papers of this supplement. Importantly, so far, the participants have been
enthusiastic about continuing in follow-up studies and we
expect that, overall, the loss to follow-up rate will be <3%.
In addition, standardisation of a large number of health
professionals operating in varied parts of the world and
monitoring the quality of data produced by different centres are always major challenges, especially in obstetric
ultrasound, a field that does not have a long tradition of
standardising practices. Considerable organisation was
required to plan and coordinate the implementation of a
single ultrasound protocol with the same ultrasound
machine in each centre. In one country, difficulty in
importing the new model, which had not yet been
approved for clinical use, delayed the start of FGLS at that
site. Nevertheless, using the same machine, specially prepared for FGLS, at each site is a major strength of the
study and should result in greater consistency of the ultrasound measurements.
Similarly, follow-up of the preterm newborns presents
considerable challenges: (1) difficulties measuring very
small infants, especially those in an incubator; (2) morbidities associated with prematurity, which may affect the measures to be taken even after discharge; (3) mortality
affecting the final sample size and the follow-up; and (4)
standardisation of feeding practices across sites, including
the promotion of breastfeeding. The overall proportion of
preterm births in this healthy, low-risk cohort is expected
to be very low (close to 5%) with a small number of births
<33+0 weeks of gestation. Nevertheless, we expect that
adherence to the protocol for the preterm babies will be
very high given the parents’ concerns for their health. This
increases power and reduces the problem of the small
number of preterm infants. Interestingly, the final rate of
preterm birth (<37+0 weeks of gestation) in this cohort can
be used as the target, lowest level for comparative purposes
in the future.
Selecting an adequately powered sample size for studies
such as this is always a compromise between statistical
estimates, logistics, cost and the different objectives of
the studies—while being aware of the need not to overextend the research team by attempting to answer too
many questions. Our first challenge was to have a sample

ª 2013 The Authors BJOG An International Journal of Obstetrics and Gynaecology ª 2013 RCOG

23

Villar et al.

size in FGLS large enough to create the cohort for the
preterm postnatal growth standards (the smallest of our
populations) and, second, to have stable outer centiles
for the birthweight for gestational age standards. We also
needed to have sufficient power to explore populationspecific growth in FGLS, in the event that population
differences did emerge from the data on the main fetal
growth indicators. Having said that, we are confident of
the power of this study, which will be analysed using
statistical methods appropriate for longitudinal (repeated)
measurements.31,43
Based on the findings of MGRS,44–46 we think it unlikely
that each study population will have its own distinct
growth pattern. Nevertheless, it is possible that some of the
fat-dependent ultrasound measures such as abdominal circumference will differ in certain populations, although the
challenge here, as in all similar studies, is to define what is
a biologically relevant ‘distinct growth pattern’. We shall
explore this question in sensitivity analyses, having decided
a priori, following MGRS principles, that fat-free mass
indicators, e.g. CRL and head circumference, are the markers of fetal growth to assess variability across and within
populations. Constructing growth curves is a sophisticated
statistical task but the experience gained in MGRS will help
considerably.31
However, perhaps the most important challenge to overcome is maintaining the motivation of the local investigators
and data collection teams throughout the project. They are
the people who will guarantee the quality of the project, the
achieved sample size and eventually the implementation of
its results. As we are close to the final sample needed, our
experience to date has confirmed that the teams we selected
are undertaking research of the highest quality.
The specific aims of this project are to produce new,
scientifically valid tools for use at different levels of perinatal care to complement existing clinical tools. We shall
produce a new, international, symphyseal–fundal height
chart for use in routine antenatal care worldwide and
ultrasound standards to evaluate fetal growth. However,
we have debated the obvious question: what to do if
IUGR is diagnosed using these charts? To contribute to
the debate, we have published a series of review papers
critically evaluating interventions for fetal growth restriction described in several randomised controlled trials17,47
and another group’s recent update.48 Unfortunately, there
are too few interventions for treating IUGR, other than
planned elective delivery. This explains why referral to an
adequate level of perinatal care is so important an
option. Finally, the results from the epidemiological studies of the phenotypes of preterm and IUGR syndromes
could contribute to a better understanding, and therefore
identification of, more preventive and clinical interventions.
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Our study focuses on helping clinicians to detect
impaired fetal growth accurately, which should avoid incorrect diagnoses and, thereby, iatrogenic preterm births. We
strongly believe that the misuse of technology, including
ultrasound, is one of the factors responsible for unnecessary
medical interventions. We think that interventions can only
be effective if they focus on the factors responsible for the
growth restriction. Small for gestational age is a very heterogeneous condition and it is unlikely that a ‘silver bullet’
will resolve all cases even if correctly detected. Overall, we
believe that accurate early identification (avoiding false positives) and appropriate referral to adequate levels of obstetric and newborn care will have a great impact on neonatal
morbidity and mortality, as well as resource allocation in
developing countries.
In summary, the new fetal international standard will
facilitate the correct interpretation of uterine height values
as a first level of screening for fetal growth alterations. It
will be complemented by ultrasound scanning at levels of
care where it is required by the risk profile of the population served. It is anticipated, therefore, that the new set of
complementary charts will have a major clinical impact on
overall antenatal and postnatal care. For example, in the
case of ultrasound screening, use of the charts is likely to
result in fewer unnecessary interventions, such as caesarean sections, because of an incorrect diagnosis of IUGR.
We anticipate the newborn standards being used in all
institutions where perinatal care is delivered, including
rural areas, and the preterm standards being used in
NICUs and at other levels of secondary care. We believe
this is the first, comprehensive approach – from early
pregnancy to infancy – to evaluate growth and its consequences and that it is the most effective way to improve
growth monitoring and clinical care for pregnant women
and newborns.
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